What is NovoCure's interest income (expense), nonoperating?

NovoCure (NVCR) reported interest income (expense), nonoperating of -$1.84M in Q1 2026.

How has NovoCure's interest income (expense), nonoperating changed year-over-year?

NovoCure's interest income (expense), nonoperating decreased by 124.3% year-over-year, from $7.57M to -$1.84M.

What is the long-term trend for NovoCure's interest income (expense), nonoperating?

Over 2 years (2023 to 2025), NovoCure's interest income (expense), nonoperating has grown at a -33.6% compound annual growth rate (CAGR), from $41.13M to $18.11M.

NovoCure NVCR Interest Income (Expense), Nonoperating

Interest Income (Expense), Nonoperating at other companies

Jazz PharmaceuticalsJAZZ

——

Fortrea Holdings Inc.FTRE

——

Stoke Therapeutics, Inc.STOK

——

Immunovant, Inc.IMVT

——

Other financials

Income statement

See full

Revenue$174.1M+12.3%

Gross profit$135.1M+16.0%

Operating income-$67.4M-78.1%

Net income-$71.1M-107%

EPS (diluted)-$0.62-100%

Balance sheet

See full

Cash & equivalents$87.5M-31.2%

Total debt$39.5M-2.1%

Total equity$330.7M-8.6%

Total assets$787.9M-36.9%

Cash flow

See full

Operating cash flow-$13.5M+62.1%

CapEx$5.2M-51.4%

Free cash flow-$18.7M+59.7%

Valuation

See full

Market cap$1.7B-36.7%

Enterprise value$1.66B-36.3%

P/S2.5×-1.8×

Profitability

See full

Gross margin75.2%-2.0pp

Operating margin-27.2%+0.4pp

Net margin-25.7%-0.7pp

FCF margin-7.1%-2.0pp

Returns & leverage

See full

Return on equity-50%+5.4pp

Debt / equity0.1×0.0×

Current ratio2.9×+1.4×

Where this comes from

Reported directly by NovoCure in its filing.

Tagged under the XBRL concept us-gaap:InterestIncomeExpenseNonoperatingNet.

The official record: NovoCure’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about NovoCure's interest income (expense), nonoperating.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is NovoCure's interest income (expense), nonoperating?: NovoCure (NVCR) reported interest income (expense), nonoperating of -$1.84M in Q1 2026.
How has NovoCure's interest income (expense), nonoperating changed year-over-year?: NovoCure's interest income (expense), nonoperating decreased by 124.3% year-over-year, from $7.57M to -$1.84M.
What is the long-term trend for NovoCure's interest income (expense), nonoperating?: Over 2 years (2023 to 2025), NovoCure's interest income (expense), nonoperating has grown at a -33.6% compound annual growth rate (CAGR), from $41.13M to $18.11M.